Literature DB >> 16364652

Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: Preliminary pharmacological investigation.

Elisabetta Barocelli1, Vigilio Ballabeni, Veronica Manenti, Lisa Flammini, Simona Bertoni, Giovanni Morini, Mara Comini, Mariannina Impicciatore.   

Abstract

The histamine H3 receptor subtype negatively modulates the release of various neurotransmitters such as histamine, glutamate, norepinephrine, acetylcholine and many others mainly in the CNS and H3 antagonists have been developed to treat central diseases characterized by neurotransmission disturbance such as schizophrenia, memory/learning and sleep disorders. In search for non-imidazole histamine H3 receptor antagonists, currently indicated as a promising class of H3 blockers, a series of simple alkylpiperidine derivatives has been studied to attain a preliminary pharmacological profile. The compounds were characterized in vitro in terms of binding affinity, antagonistic potency and selectivity at rodent H3 receptors. The imidazole-free derivatives possessed moderate to pronounced antagonistic potency at guinea-pig ileal H3 receptor consistent with binding affinity at rat brain H3 receptors and showed a favourable receptor selectivity profile. For the compound 5, with the highest affinity at rat H3 receptors, comparable values were calculated in binding (pKi = 8.35) and functional (pA2 = 8.22) assays in SK-N-MC cells stably expressing human H3 receptors. These findings indicate to extend the investigation to pharmacokinetic property and central effects to gain deeper knowledge on the pharmacological potential of this compound.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364652     DOI: 10.1016/j.phrs.2005.11.004

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  1 in total

1.  In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity.

Authors:  Simona Bertoni; Vigilio Ballabeni; Lisa Flammini; Francesca Saccani; Giuseppe Domenichini; Giovanni Morini; Mara Comini; Mirko Rivara; Elisabetta Barocelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-22       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.